AU2001227030A1 - Pharmaceutical composition for controlled release of an active ingredient - Google Patents

Pharmaceutical composition for controlled release of an active ingredient

Info

Publication number
AU2001227030A1
AU2001227030A1 AU2001227030A AU2703001A AU2001227030A1 AU 2001227030 A1 AU2001227030 A1 AU 2001227030A1 AU 2001227030 A AU2001227030 A AU 2001227030A AU 2703001 A AU2703001 A AU 2703001A AU 2001227030 A1 AU2001227030 A1 AU 2001227030A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
active ingredient
controlled release
release
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001227030A
Inventor
Shailesh Bhamare
Chandrashekhar S. Kandi
Rajesh S. Kshirsagar
Himadri Sen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Laboratories Ltd
Original Assignee
Lupin Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Laboratories Ltd filed Critical Lupin Laboratories Ltd
Publication of AU2001227030A1 publication Critical patent/AU2001227030A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
AU2001227030A 2000-11-22 2000-11-22 Pharmaceutical composition for controlled release of an active ingredient Abandoned AU2001227030A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2000/000112 WO2002041876A1 (en) 2000-11-22 2000-11-22 Pharmaceutical composition for controlled release of an active ingredient
US09/726,636 US20020103181A1 (en) 2000-11-22 2000-11-30 Pharmaceutical composition for controlled release of an active ingredient

Publications (1)

Publication Number Publication Date
AU2001227030A1 true AU2001227030A1 (en) 2002-06-03

Family

ID=26324100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001227030A Abandoned AU2001227030A1 (en) 2000-11-22 2000-11-22 Pharmaceutical composition for controlled release of an active ingredient

Country Status (3)

Country Link
US (1) US20020103181A1 (en)
AU (1) AU2001227030A1 (en)
WO (1) WO2002041876A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
WO2004016251A1 (en) * 2002-08-16 2004-02-26 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2004016250A1 (en) * 2002-08-19 2004-02-26 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US20040265323A1 (en) * 2003-05-16 2004-12-30 Mccormick Beth A. Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
DE60319982T2 (en) * 2003-09-01 2009-04-16 Jpm - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Universal composition for controlled release of active substance containing xanthan gum and sodium alginate
AR057422A1 (en) * 2005-06-29 2007-12-05 Panacea Biotec Ltd A PHARMACEUTICAL COMPOSITION OF MODIFIED LIBERATION, PREPARATION PROCESS OF THE SUCH COMPOSITION AND METHOD TO USE THE SAME
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
BRPI0821454B8 (en) 2007-12-28 2021-05-25 Acraf pharmaceutical formulation, mixture of glycogen, alginate and alkaline earth metal salts, processes for the production of a slow-release excipient, and a pharmaceutical form
WO2013043142A1 (en) * 2011-08-08 2013-03-28 Mahmut Bilgic Production method for pharmaceutical formulations comprising an isoflavone
US10806711B2 (en) * 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
WO2014160153A1 (en) 2013-03-13 2014-10-02 University Of Cincinnati Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
MX2021009755A (en) 2019-02-13 2021-11-17 Iterum Therapeutics International Ltd Combinations of beta-lactam compounds and probenecid and uses thereof.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6055486B2 (en) * 1976-02-28 1985-12-05 富山化学工業株式会社 Composition for rectal administration of a compound having a β-lactam ring
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT

Also Published As

Publication number Publication date
US20020103181A1 (en) 2002-08-01
WO2002041876A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
AU2093101A (en) Compositions for efficient release of active ingredients
WO2003002136A3 (en) Stable formulation of modified glp-1
AU2002229140A1 (en) Controlled release pharmaceutical composition
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
AU2001236457A1 (en) Compounds and compositions for delivering active agents
AU2001284985A1 (en) Compounds and compositions for delivering active agents
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
AU2001287977A1 (en) Controlled release formulations for oral administration
AU2002228119A1 (en) Thermoformable solid pharmaceutical composition for controlled release of ivabradine
AU2001252296A1 (en) A peroral pharmaceutical formulation for controlled release of a drug
AU2001221695A1 (en) Solid pharmaceutical compositions for controlled release of active substances
AU6386801A (en) System for the release of active ingredients
AU2001232948A1 (en) Controlled release of drugs
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
AU2002340573A1 (en) Powdery active ingredient formulations
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU2002351388A1 (en) Methods and compositions for controlled release of drugs
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU5820900A (en) Capsule for the controlled release of active substances
AU2001228810A1 (en) Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
AU2003214121A1 (en) A system for the controlled release of active ingredients